Cat.No. : VNV-104
Storage: -80°C Shipping: Dry ice
| Cat. No. | VNV-104 |
| Description | These viruses are wild type respiratory syncytial virus type A (RSV-A) particles which are replication-competent. This product is intended for research use only. |
| Shipping | Dry ice |
| Storage | -80°C |
| Creative Biogene ensures high-quality lentivirus particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between lentivirus particle lots. | |
| Mycoplasma | Creative Biogene routinely tests for mycoplasma contamination using a mycoplasma detection kit. Cell lines are maintained for approximately 20 passages before being discarded and replaced with a new vial of early passage cells. Approximately 2 weeks after thawing, cell culture supernatants are tested for mycoplasma contamination. Creative Biogene ensures that lentiviral products are free of mycoplasma contamination. |
| Purity | Creative Biogene evaluates the level of impurities, such as residual host cell DNA or proteins, in prepared lentiviral vectors to ensure they meet quality standards. |
| Sterility | The lentiviral samples were inoculated into cell culture medium for about 5 days and the growth of bacteria and fungi was tested. Creative Biogene ensures that the lentiviral products are free of microbial contamination. |
| Transducibility | Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of lentivirus to deliver genetic material into target cells, and assess gene expression and functional activities. |
| Proviral Identity Confirmation | All Creative Biogene lentiviral vectors are confirmed to have correctly integrated provirus using PCR. This test involves transducing cells with serial dilutions of the lentiviral vector, harvesting the cells a few days later, and isolating genomic DNA. This DNA is then used as a template to amplify a portion of the expected lentiviral insert. |
Respiratory syncytial virus (RSV) infection is a leading cause of hospitalization and mortality in infants under six months of age worldwide. Therefore, preventing RSV infection in all infants is a major unmet medical need. Here, researchers report the isolation of a potent, broadly neutralizing RSV monoclonal antibody derived from human memory B cells. The antibody, RB1, is equally potent against RSV A and B subtypes, potently neutralizes multiple clinical isolates in vitro, and is protective in vivo. It binds to a highly conserved epitope in antigenic site IV of the RSV fusion glycoprotein. RB1 is the parent antibody of MK-1654, currently in clinical development for the prevention of RSV infection in infants.
Here, the researchers evaluated the prophylactic antiviral activity of RB1 in the cotton rat (Sigmodon hispidus) model of RSV infection. A weight-based dose of RB1 was administered via a single intramuscular injection of the antibody on day 0. Serum was collected the next day to determine the circulating concentration of RB1. After blood sampling, each animal was immediately sedated and challenged with 1 × 105 pfu of RSV strain A2 or strain B 18537 via intranasal injection. Four days after viral challenge, animals were euthanized and nasal and lung tissues were collected to evaluate antibody efficacy by measuring RSV infection titers in these tissues. The lower respiratory tract (lung) EC50 values of the RB1 antibody against RSV A and RSV B strains were 1.1 μg/mL and 1.9 μg/mL, respectively (Figure 1a, c). After RB1 administration, the EC50 values of RSV A and RSV B strains in the upper respiratory tract (nasal cavity) were 9.9 μg/mL and 8.5 μg/mL, respectively (Figure 1b, d). These in vivo data indicate that RB1 exhibits potent and dose-dependent antiviral activity in the lungs and nasal cavity after infection with RSV subtypes A and B, and the potency of the two subtypes is roughly the same.
Figure 1. Efficacy of RB1 in the upper and lower respiratory tracts of cotton rats. (Tang A, et al., 2019)
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
Creative Biogene's Wild-Type Respiratory Syncytial Virus Type A (RSV-A) is exceptional. We used it for antiviral screening, and the viral titer was spot-on. The preparation arrived intact and ready to use, significantly streamlining our workflow.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.
